多发性骨髓瘤:标准风险存活,但反应缓慢和差
Yuntong Liu1,2, Jingyu Xu1,2, Wenqiang Yan1,2
1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 288 Nanjing Road, Tianjin, 300020, China.
Annals of hematology
|October 2, 2024
概括
新诊断的多发性骨髓瘤患者 (t(11;14) 单独显示出与标准风险患者相似的存活率,但反应较慢,MRD负面性较低. 这表明这种基因亚型的临床过程是惰的.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
背景情况:
- 多发性髓瘤 (MM) 是一种由遗传异质性为特征的血液性恶性瘤.
- 11;14) 转位是MM中常见的细胞遗传异常,但其预后意义仍在争论中.
- 了解特定基因变异对治疗反应和生存的影响对于个性化医学至关重要.
研究的目的:
- 评估t(11;14) 转位在新诊断的多发性髓瘤 (NDMM) 患者中的影响.
- 为了比较不同细胞遗传风险组之间的反应率,反应动力学和生存结果.
- 阐明与单独在NDMM.中t(11;14) 相关的临床过程.
主要方法:
- 对790名NDMM患者的回顾性分析.
- 患者被分为标准风险 (SR),单独,高风险 (HR) 和高风险细胞遗传异常 (HRCA) 组.
- 评估的结果包括无进展生存 (PFS),总生存 (OS),反应深度,最小残留疾病 (MRD) 阴性率和反应动力学.
主要成果:
- 与SR组相比,单独服用t(11;14) 的患者具有相似的PFS和OS.
- 单独治疗的t(11;14) 组呈现出明显较低的MRD阴性率 (60.0%vs. 76.0%) 和较慢的反应动力学 (对MRD阴性的中位时间:9.19个月vs. 4.25-4.27个月).
- 与其他组不同的是,MRD状态并没有显著影响t(11;14) 单独组的PFS或OS.
结论:
- 在NDMM中单独的t(11;14) 基因亚型与生存时间与标准风险相比较.
- 尽管生存率相似,但单独的t(11;14) 具有较慢的反应发作和更低的缓解深度的特征.
- 这些发现表明,NDMM患者的临床过程相对惰,具有孤立的t.
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:07Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
01:27Tumor Immunotherapy
489
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
489
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K